Table 2.
Baseline patient and disease characteristics
| Characteristic | N=27 |
| Median age, years (range) | 56 (28–70) |
| Sex, n (%) | |
| Female | 16 (59) |
| Male | 11 (41) |
| Race, n (%) | |
| White | 21 (78) |
| Asian | 2 (7) |
| Unknown/other | 4 (15) |
| ECOG performance status, n (%) | |
| 0 | 11 (41) |
| 1 | 16 (59) |
| Median prior cancer treatments, no (range) | 3 (1–10) |
| Median time since last cancer treatment, weeks (range) | 13 (4–392) |
| Cancer type, n (%) | |
| Cervical | 3 (11) |
| Pancreatic | 3 (11) |
| Uterine | 2 (7) |
| Carcinoma of unknown primary | 2 (7) |
| Other* | 17 (63) |
| PD-L1 expression status,† n (%) | |
| High | 1 (4) |
| Low | 5 (19) |
| None | 15 (56) |
| Unknown/not evaluable | 6 (22) |
*One patient each had anal squamous cell carcinoma, estrogen receptor–positive breast cancer, colon carcinoma, gastric cancer, glioblastoma, leiomyosarcoma, mesothelioma, neuroendocrine cancer, osteosarcoma, ovarian carcinoma, prostate non-adenocarcinoma, rectal carcinoma, squamous cell carcinoma of the head and neck, small cell lung cancer, salivary gland carcinoma, triple-negative breast cancer and testicular carcinoma.
†Measured prospectively and defined by Tumor Proportion Score (TPS) using the DAKO PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies, Santa Clara, California, USA). High expression was defined as TPS >50% membrane staining, low expression was defined as TPS ≥1% and ≤50% membrane staining, and no expression was defined as TPS <1%.
PD-L1, programmed death-ligand 1.